切换至 "中华医学电子期刊资源库"

中华实验和临床感染病杂志(电子版) ›› 2016, Vol. 10 ›› Issue (02) : 151 -156. doi: 10.3877/cma.j.issn.1674-1358.2016.02.005

临床论著

HBV基本核心启动子和前C区变异的深度测序分析
闫琳琳1, 张恒辉2, 马慧2, 刘翟3, 李伟3, 陈红松2, 邵启祥1,()   
  1. 1. 212013 镇江市,江苏大学医学院免疫学系
    2. 100044 北京,北京大学人民医院,北京大学肝病研究所,丙型肝炎及肝病免疫治疗北京市重点实验室
    3. 100078 北京,中国科学院微生物研究所生物信息中心
  • 收稿日期:2015-06-16 出版日期:2016-04-15
  • 通信作者: 邵启祥
  • 基金资助:
    国家自然科学基金(No. 81273202;No. 31400773); 国家重大科技专项(No. 2012ZX10002011-006); 江苏省临床医学科技专项(No. BL2013024)

Deep sequencing analysis of hepatitis B virus mutations in the basal core promoter and precore regions

Linlin Yan1, Henghui Zhang2, Hui Ma2, Di Liu3, Wei Li3, Hongsong Chen2, Qixiang Shao1,()   

  1. 1. Department of Immunology, School of Medicine, Jiangsu University, Zhenjiang 212013, China
    2. Beijing Key Laboratory of Hepatitis C and Immunotherapy for Liver Diseases, Peking University Hepatology Institute, Peking University People’s Hospital, Beijing 100044, China
    3. Institute of Microbiology, Chinese Academy of Sciences, Beijing 100078, China
  • Received:2015-06-16 Published:2016-04-15
  • Corresponding author: Qixiang Shao
引用本文:

闫琳琳, 张恒辉, 马慧, 刘翟, 李伟, 陈红松, 邵启祥. HBV基本核心启动子和前C区变异的深度测序分析[J/OL]. 中华实验和临床感染病杂志(电子版), 2016, 10(02): 151-156.

Linlin Yan, Henghui Zhang, Hui Ma, Di Liu, Wei Li, Hongsong Chen, Qixiang Shao. Deep sequencing analysis of hepatitis B virus mutations in the basal core promoter and precore regions[J/OL]. Chinese Journal of Experimental and Clinical Infectious Diseases(Electronic Edition), 2016, 10(02): 151-156.

目的

利用Ion Torrent PGM深度测序技术,探讨乙型肝炎病毒e抗原(HBeAg)阳性慢性乙型肝炎(CHB)患者乙型肝炎病毒(HBV)基本核心启动子和前C区突变特征。

方法

收集HBeAg阳性CHB患者血清样本25例,提取HBV DNA,采用巢式PCR方法扩增HBV基本核心启动子和前C区片段,构建深度测序文库,基于Ion Torrent PGM平台深度测序,生物信息学分析突变位点及其突变率;构建HBV基本核心启动子和前C区突变型和野生型参考质粒,作为深度测序质控品。

结果

在25例HBeAg阳性CHB患者HBV基本核心启动子和前C区检出流行率达20%的突变位点10个:G1746A、A1752G/T、T1753C/G、A1762T、G1764A、C1817G/A、T1825C/A、A1846T、G1896A、G1899A;G1746A和T1825C/A的流行率分别达92%和100%。突变位点在HBV B基因型和C基因型感染者的分布情况显示,A1752G/T和G1896A主要流行于B基因型感染者(63.6% vs 0.0%,χ2 = 12.374、P = 0.0007;72.7% vs 28.6%,χ2 = 4.812、P = 0.0472),A1762T和G1764A主要流行于C基因型感染者(27.3% vs 78.6%,χ2 = 6.579,P = 0.0172);C基因型感染者A1762T/G1764A突变率显著高于B基因型感染者,但差异无统计学意义(25.7% ± 28.4% vs 68.4% ± 42.7%,t = 1.614、P = 0.1326)。25例HBeAg阳性CHB患者中,32.0%患者仅有A1762T/G1764A突变,24.0%患者仅有G1896A突变,24.0%患者同时携带A1762T/G1764A和G1896A突变。

结论

深度测序分析可用于定量检测HBV基本核心启动子和前C区突变,为HBV突变研究的临床应用提供了技术平台。

Objective

To explore the characteristics of mutations in the basal core promoter (BCP) and precore (PC) regions of hepatitis B virus (HBV) genome in HBeAg-positive patients with chronic hepatitis B (CHB) using Ion Torrent Personal Genome Machine (PGM) deep sequencing.

Methods

Serum samples from 25 HBeAg-positive patients with CHB were collected, which were used for HBV DNA extraction. Nested PCR was used to amplify the BCP and PC regions of HBV genome. The PCR product was subjected to deep sequencing libraries preparation and subsequently Ion Torrent PGM sequencing. The variants and mutant percentages were detected through bioinformatics analysis. HBV BCP/PC wild type and mutant type reference plasmids were constructed, which were used as quality control in deep sequencing.

Results

Ten single nucleotide polymorphisms (SNPs) that had variant types with prevalence of greater than 20% were observed in the BCP and PC regions among the 25 HBeAg-positive patients with CHB: G1746A, A1752G/T, T1753C/G, A1762T, G1764A, C1817G/A, T1825C/A, A1846T, G1896A and G1899A; the prevalence of G1746A and T1825C/A were 92% and 100%, respectively. The prevalence of these mutants was analyzed in patients with different HBV genotype infection. The A1752G/T and G1896A were mainly prevalent in genotype B infection HCV patients (63.6% vs 0.0%, χ2 = 12.374, P = 0.0007 and 72.7% vs 28.6%; χ2 = 4.812, P = 0.0472), A1762T and G1764A were mainly prevalent in genotype C HCV infection patients (27.3% vs 78.6%; χ2 = 6.579, P = 0.0172). Patients with genotype C HCV infection had higher A1762T/G1764A mutant percentages than those with genotype B HCV infection, but without statistical significance (25.7% ± 28.4% vs 68.4% ± 42.7%; t = 1.614, P = 0.1326). Among the 25 CHB patients with HBeAg-positive, 32.0% cases had BCP mutants only, 24.0% had PC mutant only, and 24.0% had both BCP and PC mutants.

Conclusions

Deep sequencing could be used for quantification of HBV BCP and PC mutants, providing a suitable technology platform for the clinical application of HBV mutant research.

图1 HBV BCP(1762/1764)/PC 1896突变型和野生型参考质粒
图2 HBV BCP和PC区巢式PCR扩增产物电泳图
图3 生物信息学分析流程
表1 研究队列特征
表2 慢性乙型肝炎患者HBV BCP和PC区突变情况
表3 慢性乙型肝炎患者HBV BCP A1762T/G1764A和PC G1896A突变特征
图4 HBV BCP A1762T和G1764A突变率相关性分析
[1]
Chotiyaputta W, Lok AS. Hepatitis B virus variants[J]. Nat Rev Gastroenterol Hepatol,2009,6(8):453-462.
[2]
Gunther S, Fischer L, Pult I, et al. Naturally occurring variants of hepatitis B virus[J]. Adv Virus Res,1999,52:25-137.
[3]
郑彩霞,陈立,潘晨. 乙型肝炎病毒准种的临床意义[J/CD]. 中华实验和临床感染病杂志:电子版,2011,5(4):494-498.
[4]
Tseng TC, Liu CJ, Yang HC, et al. Higher proportion of viral basal core promoter mutant increases the risk of liver cirrhosis in hepatitis B carriers[J]. Gut,2015,64(2):292-302.
[5]
Yang HC, Chen CL, Shen YC, et al. Distinct evolution and predictive value of hepatitis B virus precore and basal core promoter mutations in interferon-induced hepatitis B e antigen seroconversion[J]. Hepatology,2013,57(3):934-943.
[6]
Nie H, Evans AA, London WT, et al. Quantitative dynamics of hepatitis B basal core promoter and precore mutants before and after HBeAg seroconversion[J]. J Hepatol,2012,56(4):795-802.
[7]
Chu CM, Lin CC, Chen YC, et al. Basal core promoter mutation is associated with progression to cirrhosis rather than hepatocellular carcinoma in chronic hepatitis B virus infection[J]. Br J Cancer,2012,107(12):2010-2015.
[8]
Yang HI, Yeh SH, Chen PJ, et al. Associations between hepatitis B virus genotype and mutants and the risk of hepatocellular carcinoma[J]. J Natl Cancer Inst,2008,100(16):1134-1143.
[9]
Chou YC, Yu MW, Wu CF, et al. Temporal relationship between hepatitis B virus enhancer II/basal core promoter sequence variation and risk of hepatocellular carcinoma[J]. Gut,2008,57(1):91-97.
[10]
Fujimoto M, Moyerbrailean GA, Noman S, et al. Application of ion torrent sequencing to the assessment of the effect of alkali ballast water treatment on microbial community diversity[J]. PLoS One,2014,9(9):e107534.
[11]
Rothberg JM, Hinz W, Rearick TM, et al. An integrated semiconductor device enabling non-optical genome sequencing[J]. Nature,2011,475(7356):348-352.
[12]
Ma H, Yang RF, Wei L. Quantitative serum HBsAg and HBeAg are strong predictors of sustained HBeAg seroconversion to pegylated interferon alfa-2b in HBeAg-positive patients[J]. J Gastroenterol Hepatol,2010,25(9):1498-1506.
[13]
Fang ZL, Sabin CA, Dong BQ, et al. The association of HBV core promoter double mutations (A1762T and G1764A) with viral load differs between HBeAg positive and anti-HBe positive individuals: a longitudinal analysis[J]. J Hepatol,2009,50(2):273-280.
[14]
Dienstag JL. Hepatitis B virus infection[J]. N Engl J Med,2008,359(14):1486-1500.
[15]
Chu CM, Karayiannis P, Fowler MJ, et al. Natural history of chronic hepatitis B virus infection in Taiwan: studies of hepatitis B virus DNA in serum[J]. Hepatology,1985,5(3):431-434.
[16]
Kao JH. Role of viral factors in the natural course and therapy of chronic hepatitis B[J]. Hepatol Int,2007,1(4):415-430.
[17]
Liu CJ, Chen BF, Chen PJ, et al. Role of hepatitis B viral load and basal core promoter mutation in hepatocellular carcinoma in hepatitis B carriers[J]. J Infect Dis,2006,193(9):1258-1265.
[18]
Kao JH, Chen PJ, Lai MY, et al. Basal core promoter mutations of hepatitis B virus increase the risk of hepatocellular carcinoma in hepatitis B carriers[J]. Gastroenterology,2003,124(2):327-334.
[19]
Tseng TC, Yu ML, Liu CJ, et al. Effect of host and viral factors on hepatitis B e antigen-positive chronic hepatitis B patients receiving pegylated interferon-alpha-2a therapy[J]. Antivir Ther,2011,16(5):629-637.
[20]
Erhardt A, Reineke U, Blondin D, et al. Mutations of the core promoter and response to interferon treatment in chronic replicative hepatitis B[J]. Hepatology,2000,31(3):716-725.
[21]
Lok AS, Akarca US, Greene S. Predictive value of precore hepatitis B virus mutations in spontaneous and interferon-induced hepatitis B e antigen clearance[J]. Hepatology,1995,21(1):19-24.
[22]
Yin J, Xie J, Liu S, et al. Association between the various mutations in viral core promoter region to different stages of hepatitis B, ranging of asymptomatic carrier state to hepatocellular carcinoma[J]. Am J Gastroenterol,2011,106(1):81-92.
[23]
Kao JH, Wu NH, Chen PJ, et al. Hepatitis B genotypes and the response to interferon therapy[J]. J Hepatol,2000,33(6):998-1002.
[24]
Yu MW, Yeh SH, Chen PJ, et al. Hepatitis B virus genotype and DNA level and hepatocellular carcinoma: a prospective study in men[J]. J Natl Cancer Inst,2005,97(4):265-272.
[25]
Kao JH, Chen PJ, Lai MY, et al. Hepatitis B genotypes correlate with clinical outcomes in patients with chronic hepatitis B[J]. Gastroenterology,2000,118(3):554-559.
[1] 卢天祺, 张巍, 周康, 毕士玉, 张羽, 杨秀华. 血流向量成像技术在不同Child-Pugh分级乙肝患者左心功能评价中的价值[J/OL]. 中华医学超声杂志(电子版), 2024, 21(04): 352-360.
[2] 刘莉莉, 贾建茹, 张晶, 周大琼, 刘江雨, 曹振环. 单纯慢性乙型肝炎患者与慢性乙型肝炎合并肝脂肪变患者的临床特征横断面研究[J/OL]. 中华实验和临床感染病杂志(电子版), 2024, 18(05): 270-277.
[3] 张雨, 杨松. 世界卫生组织《慢性乙型肝炎预防、诊断、关怀及治疗指南(2024年版)》解读[J/OL]. 中华实验和临床感染病杂志(电子版), 2024, 18(03): 129-134.
[4] 陈观梅, 左璇, 廖宝林. 慢性乙型肝炎新型免疫治疗研究进展[J/OL]. 中华实验和临床感染病杂志(电子版), 2024, 18(01): 7-10.
[5] 吴方园, 孙霞, 林昌锋, 张震生. HBV相关肝硬化合并急性上消化道出血的危险因素分析[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(01): 45-47.
[6] 刘敏思, 李荣, 李媚. 基于GGT与Plt比值的模型在HBV相关肝细胞癌诊断中的作用[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 831-835.
[7] 邓万玉, 陈富, 许磊波. 肝硬化与非肝硬化乙肝相关性肝癌患者术后无复发生存比较及其影响因素分析[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(05): 670-674.
[8] 董佳, 王坤, 张莉. 预后营养指数结合免疫球蛋白、血糖及甲胎蛋白对HBV 相关慢加急性肝衰竭患者治疗后预后不良的预测价值[J/OL]. 中华消化病与影像杂志(电子版), 2024, 14(06): 555-559.
[9] 胡静, 杨秀锦, 侯志云. HBV感染患者外周血ISGs表达水平变化及其与干扰素治疗疗效的关系[J/OL]. 中华消化病与影像杂志(电子版), 2024, 14(04): 343-347.
[10] 江浩, 余宏圣, 杨碧兰, 阿布都克尤木·斯马依, 吴斌, 杨逸冬. 基于列线图模型对慢性乙型肝炎合并肝脏脂肪变性患者并发晚期肝纤维化的临床预测[J/OL]. 中华消化病与影像杂志(电子版), 2024, 14(02): 114-120.
[11] 王秀, 王义国. 益生菌联合恩替卡韦治疗乙型肝炎肝硬化临床疗效的meta分析[J/OL]. 中华消化病与影像杂志(电子版), 2024, 14(02): 164-171.
[12] 黄圣楷, 许斌, 苏健, 孙龙. 海南省2010~2020年乙型肝炎流行趋势的时间序列分析及预测[J/OL]. 中华临床医师杂志(电子版), 2024, 18(06): 555-561.
[13] 刘春林, 刘畅, 赵东岩, 李端萍, 刘建梅, 罗秋林. 利用室内质控与能力验证数据评定HBV DNA和HCV RNA测量不确定度[J/OL]. 中华临床实验室管理电子杂志, 2024, 12(02): 91-96.
[14] 李玛, 闫凌, 席云, 李尚霞, 朱冬林. HBV RNA用于监测慢性乙型肝炎患者临床治愈的研究和应用[J/OL]. 中华临床实验室管理电子杂志, 2024, 12(02): 70-74.
[15] 郭楠, 徐学俊. 富马酸替诺福韦二吡呋酯在慢性乙型肝炎患者中诱导的范科尼综合征并低磷软骨病一例[J/OL]. 中华诊断学电子杂志, 2024, 12(03): 173-177.
阅读次数
全文


摘要